These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 265071)

  • 21. Propagation and characterization of a rat myeloma cell line producing immunoglobulin E in vitro.
    Eberly K; Gavin JJ
    Proc Soc Exp Biol Med; 1979 Feb; 160(2):196-9. PubMed ID: 419146
    [No Abstract]   [Full Text] [Related]  

  • 22. Antitumor activity of a folate-cleaving enzyme, carboxypeptidase G 1 .
    Chabner BA; Chello PL; Bertino JR
    Cancer Res; 1972 Oct; 32(10):2114-9. PubMed ID: 5080761
    [No Abstract]   [Full Text] [Related]  

  • 23. [Corticosteroids in oncology].
    Cleton FJ
    Ned Tijdschr Geneeskd; 1977 Oct; 121(43):1715-20. PubMed ID: 270013
    [No Abstract]   [Full Text] [Related]  

  • 24. Properties of 5-bromodeoxyuridine-resistant lines of higher plant cells in liquid culture.
    Ohyama K
    Exp Cell Res; 1974 Nov; 89(1):31-8. PubMed ID: 4279827
    [No Abstract]   [Full Text] [Related]  

  • 25. [Antineoplastic activity of L-asparaginase].
    Grgić Z
    Lijec Vjesn; 1969 Jul; 91(7):783-6. PubMed ID: 4910066
    [No Abstract]   [Full Text] [Related]  

  • 26. [Prediction of the response to chemotherapy in acute leukemia through in-vitro incorporation of tritiated thymidine].
    Zittoun R; Bouchard M; Facquet-Danis J; Percie-Du-Sert M; Bousser J
    Ann Med Interne (Paris); 1974 Nov; 125(11):811-6. PubMed ID: 4618066
    [No Abstract]   [Full Text] [Related]  

  • 27. [Lithium carbonate in prevention of leukopenia/caused by antineoplastic drugs].
    Orlando S; Baroni MC; Crotti G; Mineo F; Capra A; Coiro V; Delsignore R
    G Clin Med; 1981 May; 62(5):351-9. PubMed ID: 6791980
    [No Abstract]   [Full Text] [Related]  

  • 28. Induction of tubuloreticular inclusions in human lymphoma cells (Raji line) related to S-phase treatment with halogenated pyrimidines.
    Hulanicka B; Barry DW; Grimley PM
    Cancer Res; 1977 Jul; 37(7 Pt 1):2105-13. PubMed ID: 861937
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of a human lymphoid cell line to evaluate interactions between prednisolone and other chemotherapeutic agents.
    Norman MR; Harmon JM; Thompson EB
    Cancer Res; 1978 Nov; 38(11 Pt 2):4273-8. PubMed ID: 279403
    [No Abstract]   [Full Text] [Related]  

  • 30. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
    Zhu XH; Shen YL; Jing YK; Cai X; Jia PM; Huang Y; Tang W; Shi GY; Sun YP; Dai J; Wang ZY; Chen SJ; Zhang TD; Waxman S; Chen Z; Chen GQ
    J Natl Cancer Inst; 1999 May; 91(9):772-8. PubMed ID: 10328107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-Bromo-2'-deoxyuridine efficiently suppresses division potential of the yeast Saccharomyces cerevisiae.
    Fujii M; Ito H; Hasegawa T; Suzuki T; Adachi N; Ayusawa D
    Biosci Biotechnol Biochem; 2002 Apr; 66(4):906-9. PubMed ID: 12036074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Rubidomycine. A new antineoplastic antibiotic].
    Soulié L
    Munch Med Wochenschr; 1968 Jun; 110(25):1539-41. PubMed ID: 5252222
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
    Frei E; Schabel FM; Goldin A
    Cancer Res; 1974 Jan; 34(1):184-93. PubMed ID: 4520419
    [No Abstract]   [Full Text] [Related]  

  • 34. [Experiences with methyl-benzyl-hydrazine (Natulan) in lymphoreticular diseases and hemoblastoses].
    Schubert JC; Martin H
    Blut; 1968; 18(1):42-7. PubMed ID: 4972003
    [No Abstract]   [Full Text] [Related]  

  • 35. Bromodeoxyuridine mutagenesis in mammalian cells is stimulated by thymidine and suppressed by deoxycytidine.
    Davidson RL; Kaufman ER
    Nature; 1978 Dec; 276(5689):722-3. PubMed ID: 732877
    [No Abstract]   [Full Text] [Related]  

  • 36. VM26 in malignant hematological diseases. A phase II study.
    Tirelli U; Carbone A; Franchin G; Galligioni E; Veronesi A; Trovo MG; Volpe R; Tumolo S; Grigoletto E
    Cancer Chemother Pharmacol; 1982; 7(2-3):173-4. PubMed ID: 6952964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased sensitivity of thymidine kinase-deficient (TK-) tumor cell lines to the cell growth inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds.
    Balzarini J; De Clercq E; Verbruggen A; Crumpacker C; Ayusawa D; Seno T
    Anticancer Res; 1986; 6(5):1077-84. PubMed ID: 2432829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Primary suspended cultures of tumor cells from transplantable ascites tumors as a model for the study of antitumor compounds].
    Ivanitskii LP; Makukho LV
    Vopr Onkol; 1973 May; 19(5):67-71. PubMed ID: 4714738
    [No Abstract]   [Full Text] [Related]  

  • 39. [Contribution of anthracyclines in treatment of lymphoproliferative disorders].
    Coiffier B
    Pathol Biol (Paris); 1987 Jan; 35(1):75-8. PubMed ID: 2436132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of incorporated halogenated analogues of thymidine on the sister-chromatid exchange frequency in human lymphocytes.
    DuFrain RJ; Garrand TJ
    Mutat Res; 1981 May; 91(3):233-8. PubMed ID: 7242552
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.